- Home
- MFIN vs EDIT Comparison
MFIN vs EDIT Comparison
Compare MFIN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- EDIT
- Stock Information
- Founded
- MFIN 1995
- EDIT 2013
- Country
- MFIN United States
- EDIT United States
- Employees
- MFIN N/A
- EDIT N/A
- Industry
- MFIN Finance: Consumer Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- EDIT Health Care
- Exchange
- MFIN Nasdaq
- EDIT Nasdaq
- Market Cap
- MFIN 243.9M
- EDIT 269.8M
- IPO Year
- MFIN 1996
- EDIT 2016
- Fundamental
- Price
- MFIN $9.85
- EDIT $3.77
- Analyst Decision
- MFIN Strong Buy
- EDIT Buy
- Analyst Count
- MFIN 1
- EDIT 11
- Target Price
- MFIN $12.00
- EDIT $4.56
- AVG Volume (30 Days)
- MFIN 33.9K
- EDIT 3.4M
- Earning Date
- MFIN 10-30-2025
- EDIT 11-03-2025
- Dividend Yield
- MFIN 4.85%
- EDIT N/A
- EPS Growth
- MFIN N/A
- EDIT N/A
- EPS
- MFIN 1.75
- EDIT N/A
- Revenue
- MFIN $332,256,000.00
- EDIT $38,901,000.00
- Revenue This Year
- MFIN N/A
- EDIT N/A
- Revenue Next Year
- MFIN $1.53
- EDIT N/A
- P/E Ratio
- MFIN $5.65
- EDIT N/A
- Revenue Growth
- MFIN 16.48
- EDIT N/A
- 52 Week Low
- MFIN $7.71
- EDIT $0.91
- 52 Week High
- MFIN $10.98
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- MFIN 46.86
- EDIT 55.63
- Support Level
- MFIN $9.78
- EDIT $3.32
- Resistance Level
- MFIN $10.15
- EDIT $4.33
- Average True Range (ATR)
- MFIN 0.31
- EDIT 0.37
- MACD
- MFIN 0.00
- EDIT -0.02
- Stochastic Oscillator
- MFIN 60.40
- EDIT 34.51
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.